GSK director reallocates 67,601.825 notional ADSs

GSK plc filed a report detailing an internal transaction by non-executive director Dr Hal Barron.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

GSK plc filed a report detailing an internal transaction by non-executive director Dr Hal Barron. On 2026-02-05, Dr Barron recorded a disposal of notional American Depositary Shares in his GSK Executive Supplemental Savings Plan account, involving 67,601.825 ADSs at $59.1700 per ADS.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GSK (GSK) disclose in this Form 6-K?

GSK disclosed a transaction by non-executive director Dr Hal Barron. He recorded a disposal of 67,601.825 notional American Depositary Shares within his GSK Executive Supplemental Savings Plan account at a price of $59.1700 per ADS on 2026-02-05.

Who is the GSK (GSK) insider involved in the reported notional ADS transaction?

The insider is Dr Hal Barron, a non-executive director of GSK plc. The filing identifies him as the person discharging managerial responsibilities connected to the disposal of 67,601.825 notional American Depositary Shares recorded in his Executive Supplemental Savings Plan account.

What type of security was involved in Dr Hal Barron’s GSK (GSK) transaction?

The transaction involved GSK plc American Depositary Shares (ADSs). The filing specifies these as the financial instrument, identified by ISIN US37733W2044, and describes the movement as a disposal of notional ADSs within Dr Barron’s Executive Supplemental Savings Plan account.

At what price were the notional GSK (GSK) ADSs disposed of in Dr Barron’s plan?

The notional American Depositary Shares were disposed of at a price of $59.1700 per ADS. This single recorded transaction covered 67,601.825 notional ADSs in Dr Barron’s GSK Executive Supplemental Savings Plan account on the stated transaction date.

When did the reported notional ADS transaction for GSK (GSK) take place?

The reported transaction took place on 2026-02-05. On that date, GSK non-executive director Dr Hal Barron recorded a disposal of 67,601.825 notional American Depositary Shares at a price of $59.1700 within his Executive Supplemental Savings Plan account.

Where were the GSK (GSK) notional ADS transactions by Dr Barron executed?

The filing lists the place of the transaction as N/A. This aligns with the description of the event as a disposal of notional American Depositary Shares within Dr Barron’s GSK Executive Supplemental Savings Plan account rather than a trade conducted on a specific trading venue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/09/2026 - 11:25 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Disposal of notional ADSs following Dr Barron's election to re-allocate funds within his GSK Executive Supplemental Savings Plan account
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$59.1700	67,601.825

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-05
f)	Place of the transaction	N/A

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: February 09, 2026

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

Source: View Original Filing on SEC EDGAR